MTOR and cancer: It has been proposed that the anti-cancer properties of metformin result from both direct effects on cancer cells, particularly through inhibition of the AMPK/mTOR pathway [10], and indirect effects on the host, by virtue of its blood glucose-lowering properties and anti-inflammatory effects [11, 12].